ArticleBlood2024

Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.

Francesca Alvarez Calderon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.